PL2311972T3 - Rekombinowane n-glikozylowane białka z komórek prokariotycznych - Google Patents

Rekombinowane n-glikozylowane białka z komórek prokariotycznych

Info

Publication number
PL2311972T3
PL2311972T3 PL10179208T PL10179208T PL2311972T3 PL 2311972 T3 PL2311972 T3 PL 2311972T3 PL 10179208 T PL10179208 T PL 10179208T PL 10179208 T PL10179208 T PL 10179208T PL 2311972 T3 PL2311972 T3 PL 2311972T3
Authority
PL
Poland
Prior art keywords
recombinant
proteins
glycosylated proteins
procaryotic cells
glycosylated
Prior art date
Application number
PL10179208T
Other languages
English (en)
Polish (pl)
Inventor
Markus Aebi
Michael Kowarik
Umesh Ahuja
Original Assignee
Eth Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eth Zuerich filed Critical Eth Zuerich
Publication of PL2311972T3 publication Critical patent/PL2311972T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25Shigella (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/01Hexosyltransferases (2.4.1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL10179208T 2005-05-11 2006-05-10 Rekombinowane n-glikozylowane białka z komórek prokariotycznych PL2311972T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05010276 2005-05-11
EP10179208.3A EP2311972B1 (en) 2005-05-11 2006-05-10 Recombinant N-glycosylated proteins from procaryotic cells
EP06753552A EP1888761B1 (en) 2005-05-11 2006-05-10 Recombinant n-glycosylated proteins from procaryotic cells

Publications (1)

Publication Number Publication Date
PL2311972T3 true PL2311972T3 (pl) 2015-08-31

Family

ID=37396912

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10179208T PL2311972T3 (pl) 2005-05-11 2006-05-10 Rekombinowane n-glikozylowane białka z komórek prokariotycznych

Country Status (19)

Country Link
US (3) US8753864B2 (OSRAM)
EP (3) EP2853600B1 (OSRAM)
JP (3) JP5356807B2 (OSRAM)
KR (2) KR101408653B1 (OSRAM)
CN (2) CN101360831B (OSRAM)
AT (1) ATE483027T1 (OSRAM)
AU (1) AU2006245969B8 (OSRAM)
CA (1) CA2607595C (OSRAM)
CY (1) CY1116285T1 (OSRAM)
DE (1) DE602006017207D1 (OSRAM)
DK (2) DK1888761T3 (OSRAM)
ES (3) ES2535084T3 (OSRAM)
HK (1) HK1205193A1 (OSRAM)
HR (1) HRP20150312T1 (OSRAM)
IL (2) IL187293A (OSRAM)
PL (1) PL2311972T3 (OSRAM)
PT (2) PT1888761E (OSRAM)
SI (1) SI2311972T1 (OSRAM)
WO (1) WO2006119987A2 (OSRAM)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
PT1481057E (pt) 2002-03-07 2006-05-31 Eidgenoess Tech Hochschule Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CN101072789B (zh) 2004-01-08 2013-05-15 生物种属学股份公司 肽的o-连接的糖基化
WO2005120546A2 (en) 2004-03-03 2005-12-22 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
MX2007008229A (es) 2005-01-10 2007-09-11 Neose Technologies Inc Factor estimulador de colonias de granulocitos glicopegilado.
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
EA017770B1 (ru) 2007-04-03 2013-03-29 Биодженерикс Аг Способы лечения с использованием гликопэгилированного g-csf
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
KR101589554B1 (ko) 2008-01-03 2016-02-01 코넬 리서치 파운데이션 인코포레이티드 원핵생물에서의 글리코실화 단백질 발현
CA2711503A1 (en) * 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
PT2257307T (pt) * 2008-02-20 2018-10-22 Glaxosmithkline Biologicals Sa Bioconjugados preparados a partir de proteínas n-glicosiladas recombinantes de células procariotas
EP2626080A3 (en) 2008-02-27 2014-03-05 Novo Nordisk A/S Conjugated factor VIII molecules
BRPI1010283B8 (pt) * 2009-03-27 2021-05-25 Eidgenoessische Technische Hochschule Zuerich salmonella enterica apresentando n-glicano de c.jejuni ou derivados do mesmo, seu uso, método de produção e composição farmacêutica, alimento ou ração, aditivo alimentar ou de ração compreendendo a mesma
KR101855380B1 (ko) 2009-11-19 2018-05-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 원핵세포에서 면역원성 폴리사카라이드를 제조하는 생합성 시스템
EP2545081B1 (en) 2010-02-11 2015-01-28 The Governors of the University of Alberta N-Linked Glycan Compounds
HUE037956T2 (hu) 2010-05-06 2018-09-28 Glaxosmithkline Biologicals Sa Kapszuláris Gram-pozitív bakteriális biokonjugátum vakcinák
CA2809890A1 (en) * 2010-09-03 2012-03-08 The Governors Of The University Of Alberta Peptide containing multiple n-linked glycosylation sequons
EP2753353A1 (en) * 2011-09-06 2014-07-16 Glycovaxyn AG Bioconjugate vaccines made in prokaryotic cells
AU2013343520B2 (en) 2012-11-07 2017-09-28 Glaxosmithkline Biologicals S.A. Production of recombinant vaccine in E. Coli by enzymatic conjugation
AU2014206799B9 (en) 2013-01-17 2018-05-10 Janssen Pharmaceuticals, Inc. MDR E. coli specific antibody
WO2014111724A1 (en) 2013-01-18 2014-07-24 London School Of Hygiene And Tropical Medicine Glycosylation method
GB201301085D0 (en) 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
AU2014232722B2 (en) 2013-03-15 2017-03-09 Jiangsu Yahong Meditech Co., Ltd. Base addition salts of nitroxoline and uses thereof
CN105307677B (zh) * 2013-04-05 2019-08-02 阿尔伯塔大学理事会 弯曲杆菌疫苗
KR20160062169A (ko) * 2013-10-11 2016-06-01 글리코박신 아게 숙주 세포 변형 방법
FI3110441T3 (fi) 2014-02-24 2024-05-06 Glaxosmithkline Biologicals Sa Uusi polysakkaridi ja sen käyttöjä
CN106794237B (zh) * 2014-04-17 2022-04-12 葛兰素史密丝克莱恩生物有限公司 经修饰的宿主细胞及其用途
MX378792B (es) 2014-08-08 2025-03-10 Glaxosmithkline Biologicals Sa Células hospederas modificadas y oligosacáridos híbridos para su uso en producción de bioconjugados.
EP3240895B1 (en) * 2014-12-30 2022-01-26 GlaxoSmithKline Biologicals S.A. Compositions and methods for protein glycosylation
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
WO2018140717A1 (en) * 2017-01-27 2018-08-02 University Of Florida Research Foundation Incorporated A food safety vaccine to control salmonella enterica and reduce campylobacter in poultry
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
US11898187B2 (en) 2017-08-15 2024-02-13 Northwestern University Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
TW202003023A (zh) 2018-03-12 2020-01-16 美商詹森藥物公司 針對尿路感染之疫苗
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
US11725224B2 (en) 2018-04-16 2023-08-15 Northwestern University Methods for co-activating in vitro non-standard amino acid (nsAA) incorporation and glycosylation in crude cell lysates
US12098433B2 (en) 2018-08-03 2024-09-24 Northwestern University On demand, portable, cell-free molecular sensing platform
CN113227125A (zh) 2018-12-12 2021-08-06 葛兰素史密丝克莱恩生物有限公司 用于o-连接的糖基化的修饰的载体蛋白
WO2020146814A1 (en) 2019-01-11 2020-07-16 Northwestern University Bioconjugate vaccines' synthesis in prokaryotic cell lysates
WO2020185451A2 (en) 2019-03-04 2020-09-17 Northwestern University Riboswitch-based fluoride sensing in cell-free extract
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
EP3941516A1 (en) 2019-03-18 2022-01-26 Janssen Pharmaceuticals, Inc. Bioconjugates ofe col! o-antigen polysaccharides. methods of production thereof. andmethods of use thereof
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US12226410B2 (en) 2019-10-18 2025-02-18 Northwestern University Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
CA3168108A1 (en) 2020-01-16 2021-07-22 Janssen Pharmaceuticals, Inc. Fimh mutant, compositions therewith and use thereof
CN115697396A (zh) 2020-06-18 2023-02-03 葛兰素史克生物有限公司 志贺氏菌-四价(Shigella4V)生物缀合物
EP4171625A2 (en) 2020-06-25 2023-05-03 GlaxoSmithKline Biologicals SA Klebsiella pneumoniae o-antigen vaccine
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
CN116888140A (zh) 2021-01-12 2023-10-13 杨森制药公司 FimH突变体、其组合物及其用途
CN117222427A (zh) 2021-04-01 2023-12-12 杨森制药公司 大肠杆菌o18生物缀合物的生产
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025032535A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025032534A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170204B1 (de) 1984-08-01 1991-09-25 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
AU6663294A (en) 1993-05-14 1994-12-12 Upjohn Company, The Cloned dna encoding a udp-galnac:polypeptide,n-acetylgalactos aminyltransferase
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
EP1399538A2 (en) 1999-03-02 2004-03-24 Human Genome Sciences, Inc. Engineering intracellular sialylation pathways
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
NZ522320A (en) 2000-05-12 2007-03-30 Neose Technologies Inc In vitro modification of glycosylation patterns of recombinant glycopeptides
PT1294910E (pt) 2000-06-30 2009-02-16 Vib Vzw Modificação da glicosilação de proteínas em pichia pastoris
DE10113573A1 (de) * 2001-03-20 2002-02-28 Messer Griesheim Gmbh Verfahren zum Regenerieren von Schwefelsäure aus schwefelhaltigen Reststoffen
PT1481057E (pt) 2002-03-07 2006-05-31 Eidgenoess Tech Hochschule Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota
US20040265954A1 (en) 2002-03-07 2004-12-30 Markus Aebi System and method for the production of recombinant proteins
CN1671722A (zh) * 2002-08-01 2005-09-21 加拿大国家研究院 弯曲菌的聚糖和糖肽

Also Published As

Publication number Publication date
IL226857A (en) 2017-08-31
IL187293A (en) 2013-06-27
WO2006119987A2 (en) 2006-11-16
EP1888761B1 (en) 2010-09-29
EP1888761A2 (en) 2008-02-20
KR101524636B1 (ko) 2015-06-03
JP5827303B2 (ja) 2015-12-02
US20160326563A1 (en) 2016-11-10
EP2853600A1 (en) 2015-04-01
ES2535084T3 (es) 2015-05-05
AU2006245969A1 (en) 2006-11-16
US20100062484A1 (en) 2010-03-11
AU2006245969B8 (en) 2011-08-25
JP5687637B2 (ja) 2015-03-18
EP2311972B1 (en) 2015-01-21
HK1156983A1 (en) 2016-11-25
KR20140019482A (ko) 2014-02-14
CN103396478A (zh) 2013-11-20
JP2014042533A (ja) 2014-03-13
CN103396478B (zh) 2016-09-28
IL226857A0 (en) 2013-07-31
KR101408653B1 (ko) 2014-06-17
US8753864B2 (en) 2014-06-17
DE602006017207D1 (de) 2010-11-11
ATE483027T1 (de) 2010-10-15
IL187293A0 (en) 2008-04-13
PT1888761E (pt) 2011-01-03
JP5356807B2 (ja) 2013-12-04
SI2311972T1 (sl) 2015-08-31
ES2353814T3 (es) 2011-03-07
HK1205193A1 (en) 2015-12-11
JP2012100678A (ja) 2012-05-31
HK1113588A1 (en) 2008-10-10
CA2607595A1 (en) 2006-11-16
US9551019B2 (en) 2017-01-24
WO2006119987A3 (en) 2007-03-08
EP2311972A1 (en) 2011-04-20
HRP20150312T1 (hr) 2015-07-31
AU2006245969B2 (en) 2011-06-02
DK1888761T3 (da) 2010-11-01
PT2311972E (pt) 2015-05-13
EP2853600B1 (en) 2018-09-19
DK2311972T3 (en) 2015-04-27
US20140323700A1 (en) 2014-10-30
CN101360831B (zh) 2013-07-10
KR20080048990A (ko) 2008-06-03
JP2008539743A (ja) 2008-11-20
ES2703061T3 (es) 2019-03-06
CY1116285T1 (el) 2017-02-08
CA2607595C (en) 2018-11-27
CN101360831A (zh) 2009-02-04

Similar Documents

Publication Publication Date Title
IL226857A (en) Recombinant proteins that underwent glycosylation at site n correspond to prokaryotes
TNSN08064A1 (en) Albumin fusion proteins
MX336807B (es) Composiciones y metodos para producir una composicion.
MX2009002816A (es) Proteinas de fusion de albumina.
WO2005077042A3 (en) Albumin fusion proteins
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
WO2007146038A3 (en) Albumin fusion proteins
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
IL213319A (en) Polylysis peptides for use in the treatment of bacterial infections
NZ591415A (en) Haemophilus influenzae type B
PT1991680E (pt) Sistema para a expressão de componentes ortogonais de tradução em células hospedeiras eubacterianas
MX2009005460A (es) (s)-n-estereoisomeros de analogos de 7,8-saturados-4,5-epoxi-morfi nano.
WO2007076162A3 (en) Antimicrobial cathelicidin peptides
SG165339A1 (en) Incorporation of non-naturally encoded amino acids into proteins
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
TW200740841A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
WO2007060213A3 (en) Erythropoietin polypeptides and uses thereof
EP1978994A4 (en) BMP-7 VARIANTS COMPOSITIONS, METHODS AND USES
MX2007005520A (es) Polipeptidos que tienen actividad antimicrobiana y polinucleotidos que codifican los mismos.
WO2006017355A3 (en) Improved aprotinin variants
TW200734350A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
WO2006047728A3 (en) Bmp gene and fusion protein